Editorial draft — not for publication yet. Mirtazapine content needs clinical and legal review before publication. This page is general information and is not advice about an individual prescription.

In short

Miramind is a Bangladesh brand of mirtazapine made by Biopharma Limited; its manufacturer insert lists 7.5 mg and 15 mg tablets for depression. In the UK, mirtazapine is a prescription antidepressant indicated in product information for adult major depression. It can cause sleepiness, increased appetite and weight gain. Sedation does not make it a routine insomnia medicine, and anxiety treatment should be based on a clinical assessment and UK guidance.

Miramind UK product status

Biopharma Limited’s product insert identifies Miramind as mirtazapine USP 7.5 mg and 15 mg film-coated tablets in Bangladesh. NHS describes mirtazapine as prescription-only in the UK, and the emc lists UK mirtazapine products from multiple manufacturers. Those ingredient-level records do not authenticate an individual Miramind pack or establish UK authorisation or supply of that exact brand. Check the live MHRA Products database or ask a UK pharmacist about the exact product.

What does the manufacturer say about Miramind?

Biopharma’s Bangladesh insert lists Miramind (mirtazapine) for depression. UK product information indicates mirtazapine tablets for adult episodes of major depression. Anxiety and sleep symptoms may occur alongside depression, but those searches should not be confused with a product indication or a reason to self-start an overseas pack.

  • Bangladesh product information identifies Miramind as mirtazapine in 7.5 mg and 15 mg film-coated tablets.
  • UK product information indicates mirtazapine for episodes of major depression in adults; the medicine is prescription-only.
  • NICE GAD guidance recommends an SSRI when medication is chosen; mirtazapine is not listed as a routine first-choice medicine for GAD alone.
  • Mirtazapine can cause sleepiness and may be taken in the evening, but it is not indicated as a routine insomnia medicine in the selected UK product information.
  • A UK listing for the generic ingredient does not verify the authorisation, contents or supply route of a particular Miramind pack.

The selected UK mirtazapine tablet SmPC indicates treatment of episodes of major depression in adults. The exact formulation and product leaflet should be checked for the medicine supplied.

NICE recommends shared decision-making for depression treatment. Its GAD medicine pathway recommends an SSRI when medication is chosen, then another SSRI or an SNRI if needed; individual specialist decisions may differ.

NHS says mirtazapine is prescription-only, usually starts to work after 1 or 2 weeks, and should not be stopped suddenly because withdrawal symptoms can occur.

How does it work?

Mirtazapine is a noradrenergic and specific serotonergic antidepressant. Product information says its precise antidepressant mechanism is not fully established, although it appears to increase noradrenergic and serotonergic activity through effects on particular receptors. It can also cause sleepiness; this side effect does not predict an individual antidepressant response.

Risks and possible effects

Common effects

NHS lists sleepiness, headache, dry mouth, increased appetite and weight gain, dizziness, nausea, vomiting and diarrhoea among common effects. Not everyone experiences them.

Seek prompt advice

Contact a healthcare professional for suicidal thoughts, unusually elevated mood, jaundice, or signs of infection such as fever, sore throat or mouth ulcers. Call 999 for suspected anaphylaxis or another life-threatening emergency.

Safety information

  • Tell the prescriber about bipolar disorder or past mania, epilepsy, liver or kidney disease, heart conditions, diabetes, allergies, pregnancy or breastfeeding, and all medicines and supplements.
  • Do not take mirtazapine with an MAOI. Ask a prescriber or pharmacist to check antidepressants, opioids, benzodiazepines, carbamazepine, St John’s wort and every other medicine.
  • Avoid alcohol because it may increase drowsiness. Do not drive, cycle in traffic or use machinery if sleepy, dizzy or unable to concentrate.
  • Do not stop suddenly. Contact the prescriber for an individual plan if you want to reduce or change treatment.
  • Miramind is identified in Bangladesh product information. A brand name or foreign leaflet does not authenticate an overseas pack or establish its UK authorisation.

Miramind is a Bangladesh brand of mirtazapine

Biopharma Limited’s insert identifies Miramind as mirtazapine USP and lists film-coated 7.5 mg and 15 mg tablets. These are manufacturer details for the Bangladesh brand; they do not verify the identity or supply status of an individual pack.

In the UK, mirtazapine is a prescription-only antidepressant. The emc lists UK products containing the generic ingredient in several forms, but this does not confirm that Miramind itself is authorised for UK supply. Ask a pharmacist to check the exact brand, strength and manufacturer.

Depression, anxiety and sleep are different search intents

UK product information indicates mirtazapine for episodes of major depression in adults. NICE recommends an SSRI when medication is chosen for generalised anxiety disorder; mirtazapine is not the routine first-choice medicine in that pathway. A specialist may sometimes make an individual off-label decision, which should be explained and monitored.

Mirtazapine can cause sleepiness and is usually taken before bedtime, but sleepiness is an adverse effect, not proof that the medicine is a sleeping tablet. It is not indicated as routine insomnia treatment in the selected UK product information.

How long it takes, side effects and review

NHS says mirtazapine may start working after 1 or 2 weeks, but it can take longer to judge improvement. Sleepiness, increased appetite and weight gain are common topics to discuss. NICE recommends an early follow-up after starting antidepressant medication, with earlier review for some people at increased risk.

Do not change or stop the dose on your own. NHS advises gradual reduction with a prescriber because stopping suddenly can cause withdrawal symptoms. Seek urgent help for severe allergic symptoms, suicidal thoughts, possible mania, jaundice or signs of infection.

If you have a Miramind pack or need urgent advice

Check the active ingredient, strength, dosage form, manufacturer and country on the pack. Use the MHRA Products database or ask a UK pharmacist about current product status; an authorised mirtazapine product does not authenticate a different overseas brand.

For an overdose, NHS says to call 111 if more than prescribed was taken; call 999 for severe symptoms or difficulty waking. Keep the package or leaflet available for the clinician.

Frequently asked questions

What is the generic name of Miramind?

Miramind is a brand of mirtazapine, according to Biopharma Limited’s Bangladesh product insert.

What is Miramind used for?

Biopharma’s insert lists Miramind (mirtazapine) for depression. UK product information indicates mirtazapine for adult episodes of major depression.

Is Miramind available in the UK?

The Bangladesh manufacturer listing does not establish UK authorisation of the brand or any particular pack. Mirtazapine generic products are listed in UK medicine information; check the exact brand with the MHRA database or a pharmacist.

Can Miramind be used for anxiety?

Miramind contains mirtazapine. NICE’s routine GAD medicine pathway recommends an SSRI, then another SSRI or an SNRI if needed. A prescriber can discuss any individual off-label use.

Is Miramind a sleeping tablet?

No. Mirtazapine can cause sleepiness, but UK product information indicates it for adult depression rather than routine insomnia.

Can I stop mirtazapine suddenly?

No. NHS advises speaking with a doctor and reducing it gradually because withdrawal symptoms can occur.

Explore the detailed miramind (mirtazapine) guides

Each guide answers a different practical question. Advice is specific to mirtazapine and should be checked against your own product leaflet and prescription.

Sources and review

This draft was checked against the sources below on 3 October 2026. It still requires clinical and legal review before publication.

Editorial status: UK clinical and product-status review required before publication.